DreaMed Diabetes launches evaluation of a new treatment platform with Yale New Haven Health

Wednesday, March 17, 2021

New Haven, CT, USA/Tel Aviv, Israel, March 2021-DreaMed Diabetes Ltd., a developer of the personalized, cloud-based diabetes management solution, and Yale New Haven Health System (YNHHS), a nonprofit healthcare system with headquarters in Connecticut, announced a collaboration to comprehensively assess the real-world use of DreaMed’s Advisor platform in optimally treating and managing people with diabetes. The partnership forged by the Health System’s Center for Health Care Innovation will involve onboarding 100 persons with diabetes from the Yale Pediatric Diabetes Clinic who will be followed either in person with supplemental virtual visits or entirely in remote fashion for six months’ duration. It will evaluate the workflow, satisfaction and financial aspects of adopting AI-based decision support systems, as well as a remote patient monitoring protocol.

Remote medical solutions have taken center stage in recent years, and the continued pandemic has made them a necessity. Such solutions have greatly enhanced our capacity to manage diabetes for people more efficiently, remotely, and just as accurately.

The DreaMed platform takes in all the data from a patient’s continuous glucose monitor, or blood glucose monitor and combines that data from patients’ insulin pumps and produces a specific recommendation for each person that is then reviewed by a physician. The physician can then determine whether to alter care based on complete information from the devices and the person. Throughout the trial period, different aspects of the treatment will be measured to assess how effectively they perform compared to conventional methods. This will include both patient and physician satisfaction levels, quality of the results, and benefit to the person with diabetes in terms of overall health and financial implications.

“We’re honored to take part in a collaboration with such a highly regarded health system like Yale New Haven,” says Eran Atlas, Co-Founder and CEO of DreaMed Diabetes. “Having our software utilized as a strategy that allows for both virtual and in person visits is a necessity in the era of COVID-19 and the future of care, and its use over the span of six months will fully demonstrate how our platform manages the challenges while positively affecting a person’s quality of life.”

DreaMed’s Advisor takes diabetes care forward by making the insulin pump and glucose monitoring technology an invaluable element in balancing the condition. The DreaMed Advisor platform offers personalized optimization of insulin therapy management, driven by a technology that runs on artificial intelligence (AI) and algorithms. The platform’s purpose is to assist medical professionals in the management of people with Type 1 diabetes, who use insulin pumps, providing personalized recommendations on how to adjust a patient’s insulin therapy. Recommendations are based on analysis of information derived from CGM, glucometers, insulin pumps and the use of event-oriented data.

“It’s an exciting time for solutions aimed at managing diabetes and remote protocols could create a shift in how we manage the condition,” says Jennifer Sherr, MD, PhD, pediatric endocrinologist at Yale New Haven Children’s Hospital and associate professor of pediatrics, Yale School of Medicine. “While persons with diabetes are generating a wealth of diabetes data, the interpretation of this data and optimization of the treatment regimen is often relegated to quarterly in clinic visits. As insulin needs constantly evolve for youth with diabetes the use of more frequent dose adjustments may help more youth attain targeted glycemia.”

Yale New Haven Health (YNHHS), the largest and most comprehensive healthcare system in Connecticut, is recognized for advanced clinical care, quality, service, cost effectiveness and commitment to improving the health status of the communities it serves. YNHHS includes five hospitals – Bridgeport, Greenwich, Lawrence + Memorial, Westerly and Yale New Haven hospitals, several specialty networks and Northeast Medical Group, a non-profit medical foundation with several hundred community-based and hospital-employed physicians. YNHHS is affiliated with Yale University and Yale Medicine, the clinical practice of the Yale School of Medicine and the largest academic multi-specialty practice in New England. Yale New Haven Hospital is the primary teaching hospital of Yale School of Medicine. www.ynhhs.org

Similar Articles


Outpatient Pharmacy Services at YNHHS earns URAC 4.0 re-accreditation in Specialty Pharmacy

New Haven, CT (April 30, 2021) - Yale New Haven Health (YNHHS) is proud to announce that its Outpatient Pharmacy Services has earned full URAC 4.0 re-accreditation in Specialty Pharmacy.


Westerly Hospital expands services with robot-assisted surgical system

Westerly, RI (April 29, 2021) ꟷ Westerly Hospital is expanding its surgical capabilities with the acquisition of the da Vinci Xi Surgical System that offers patients a minimally invasive alternative to traditional open surgery.


CDC’s National Healthcare Safety Network and Yale New Haven Health/Yale Center for Medical Informatics to Collaborate on Automated Hospital Reporting

New Haven, CT (April 29, 2021) – The Centers for Disease Control and Prevention’s (CDC) National Healthcare Safety Network[1] (NHSN) surveillance system and Yale New Haven Health (YNHHS)/Yale Center for Medical Informatics[2] today announced that they are collaborating on a project to demonstrate implementation readiness for end-to-end automation of hospital pandemic reporting from the Yale New Haven Health to NHSN.